T. Rowe Price Associates’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $10.3M | Sell |
|
|||||
|
2025
Q3 | $426M | Sell |
|
|||||
|
2025
Q2 | $307M | Sell |
|
|||||
|
2025
Q1 | $335M | Buy |
|
|||||
|
2024
Q4 | $321M | Buy |
|
|||||
|
2024
Q3 | $488M | Sell |
|
|||||
|
2024
Q2 | $446M | Buy |
|
|||||
|
2024
Q1 | $190M | Buy |
|
|||||
|
2023
Q4 | $62.6M | Buy |
|
|||||
|
2023
Q3 | $42.2M | Sell |
|
|||||
|
2023
Q2 | $74.1M | Sell |
|
|||||
|
2023
Q1 | $105M | Buy |
|
|||||
|
2022
Q4 | $149M | Buy |
|
|||||
|
2022
Q3 | $84.4M | Sell |
|
|||||
|
2022
Q2 | $115M | Sell |
|
|||||
|
2022
Q1 | $147M | Buy |
|
|||||
|
2021
Q4 | $184M | Buy |
|
|||||
|
2021
Q3 | $175M | Buy |
|
|||||
|
2021
Q2 | $62.7M | Buy |
|
|||||
|
2021
Q1 | $38.3M | Buy |
|
|||||
|
2020
Q4 | $24.1M | Sell |
|
|||||
|
2020
Q3 | $27M | Buy |
|
|||||
|
2020
Q2 | $26.9M | Buy |
|